|Mr. Charles Daniel Myers||Non-Exec. Chairman & Consultant||N/A||N/A||1954|
|Mr. Richard S. Eiswirth Jr.||CEO, Pres & Director||N/A||N/A||1968|
|Dr. Kenneth Green||Sr. VP, Chief Scientific Officer and Global Head of R&D||N/A||N/A||1958|
|Mr. David R. Holland||Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets||N/A||N/A||1964|
|Mr. J. Philip Jones||Chief Financial Officer||N/A||N/A||1964|
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has an agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat DME. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Alimera Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.